A Simple Novel Method for Determining Mortality Rates in HIV Treatment Programs Worldwide by Bisson, Gregory P.
Perspective
A Simple Novel Method for Determining Mortality Rates
in HIV Treatment Programs Worldwide
Gregory P. Bisson*
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
UNAIDS and the World Health Orga-
nization estimate that in 2009, about 33.3
million people in the world were infected
with HIV, of which approximately 5.2
million were on antiretroviral therapy
(ART). This proportion amounts to about
one-third of those currently considered to
need treatment [1,2]. In many resource-
limited settings, rates of loss to follow-up
after ART initiation, and of mortality of
those lost patients, are high but treatment
programs generally do not have the means
to actively trace all those who disappear
from care [3–5]. The combined effect is
that, as access to ART is expanded, an
increasingly large number of patient
outcomes are unknown, many deaths after
ART initiation are not counted, and
survival within treatment programs is
overestimated—at some sites by substan-
tial amounts [6,7].
For example, if 10,000 patients start
ART, 1,000 die during the ensuing year,
and all deaths are known to the clinic, the
proportion surviving at 1 year post-ART
initiation will be correctly calculated as
90%. However, if 500 of these deaths are
not discovered, and only known deaths are
counted as events, the proportion surviving
would be incorrectly estimated as 95%.
Why is this of practical interest? At the level
of the treatment program, one reason this
matters is that a reported 95% survival rate
may lead stakeholders to avoid changing
delivery of care, whereas a 90% survival
rate may trigger more scrutiny and poten-
tially beneficial change. Another program-
matic reason is that accurate outcomes data
are needed to facilitate comparisons of
outcomes in different cohorts to identify
treatment approaches that might be either
emulated or avoided.
In this issue of PLoS Medicine, Matthias
Egger and colleagues [8] report a simple
method they have created that HIV-
treatment programs can use to more
accurately estimate the proportion of pa-
tients dying in the first year after ART
initiation. The method is based on the fact
that overall program mortality is a weighted
average of mortality among those who
remained in care before death (and whose
deaths are known) and mortality among
those who were lost to follow-up (and whose
outcomes are unknown). The authors show
that once an estimate of mortality among
those who were lost is made (either by
tracing a sample of these individuals or by
usingdatafromapublishedmeta-regression
analysis of outcomes among patients lost to
follow-up [4]), then a ratio of mortality
among those lost and those remaining in
care, and the overall proportion of patients
lost to follow-up, can be used to determine a
correction factor,C. The mortality observed
before factoring in deaths among lost
patients is then multiplied by C and the
corrected proportion dying in the first year
after ART initiation is obtained. The
authors then apply this method to 11
ART programs in sub-Saharan Africa and
show that mortality estimates increase from
approximately 2% to 10% in absolute
terms. While the change before and after
correction was minimalfor many programs,
in one with 28.7% of patients lost to follow-
up, the percent dying in the first year
increased by nearly 10 times (from 1.3% to
11.2%).
Is the New Method Too
Complex? No.
If the explanation above sounds com-
plex, it does not do justice to the methods.
The authors have made a sophisticated
approach ‘‘field-ready’’ by creating a no-
mogram that program managers can use to
obtain C as long as a few basic parameters
about treatment outcomes are known.
Nomograms are graphic devices that rep-
resent mathematical functions and can be
used to very simply enable determinationof
a third unknown value when two or more
other values are known. In this case, if the
rate of loss to follow-up, and the ratio of
mortality among those lost and not lost to
follow-up, are known their values can be
marked on a graph and the value of C can
be obtained by drawing a line. The method
should be used only to correct mortality
estimates in the first year of ART and, as
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Linked Research Article
This Perspective discusses the fol-
lowing new study published in PLoS
Medicine:
Egger M, Spycher BD, Sidle J, Weigel
R, Geng EH, et al. (2011) Correcting
mortality for loss to follow-up: A
nomogram applied to antiretroviral
treatment programmes in sub-Sa-
haran Africa. PLoS Med 8: e1000390.
doi:10.1371/journal.pmed.1000390
Matthias Egger and colleagues pres-
ent a nomogram and a web-based
calculator to correct estimates of
program-level mortality for loss to
follow-up, for use in antiretroviral
treatment programs.
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patients will likely change as access to ART
expands and patients have more choices of
where to access care. Thus, the nomogram
will benefit from ongoing input and refine-
ment as global treatment metrics evolve.
Nonetheless, the accessibility of the ap-
proach is an advance. It is like a point-of-
care epidemiologic test for programs.
Challenges Remain
Perhaps the greatest challenge, howev-
er, is that there is no agreement on how to
define loss to follow-up, and useful defini-
tions of loss to follow-up should differ
depending on whether the goal of identi-
fying such losses is to monitor program-
level outcomes or to improve patient care.
In the 17 studies evaluated in the meta-
regression analysis of mortality among
patients lost to follow-up on which the
study by Egger et al. is in part based,
definitions of loss to follow-up ranged from
having missed a visit by 1 week to missing
an appointment by 6 months or more [4].
If the goal is to monitor the number of
patients within a program who are truly
still in care, increasing the number of days
late for an appointment required to meet
the definition of loss to follow-up increases,
to a point, the likelihood that patients so
categorized really are lost and will never
return [9]. From an epidemiologic per-
spective it makes sense to use a definition
of loss to follow-up that indicates that the
lost patient truly is lost. However, another
goal of monitoring clinic attendance
should be to prevent the adverse outcomes
associated with loss to follow-up, including
ART discontinuation and death, by ad-
dressing the socioeconomic factors associ-
ated with missed visits, for example. Such
factors have included but are not limited
to problems with transportation, work and
child-care responsibilities, relocation, fear
of disclosure of HIV status or other family
barriers, and use of traditional medicines
[10,11]. To the extent that loss to follow-
up initiates search efforts, preventing
adverse outcomes by monitoring visits will
require a definition of loss to follow-up
that is more sensitive but less specific,
which could translate, for example, into
investigations initiated within days, not
months, of a missed appointment.
Missed clinic visits are common [9], and
while searching for reasons behind each
missed visit could waste resources, the role
of real-time monitoring of adherence to
clinic visits should be aggressively ex-
plored, perhaps via use of community
health workers and mobile phone technol-
ogies, using real-time ART adherence
monitoring efforts as a model [12]. In
other words, from a patient care perspec-
tive, it makes sense to use a definition of
loss to follow-up that indicates that the
person could still be found.
Our Understanding of Loss to
Follow-Up Grows
Currently we know little about the
biology and behaviors that underlie loss
to follow-up, but with 5.2 million people
on ART, and more starting soon as a
result of the 2010 WHO guidelines
recommending HIV treatment earlier
during disease progression [13], a greater
understanding of loss to follow-up in its
various forms is needed in order to keep
the HIV treatment effort on track. By
addressing the effects of loss to follow-up
on programmatic mortality estimates, and
by providing monitoring efforts with a
useful new tool, Egger and colleagues have
helped address this need.
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